FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Removes Hold on Legend CAR-T Therapy

FDA removes a clinical hold against a Legend Biotech Phase 1 clinical trial of LB1901, an investigational autologous chimeric antigen receptor T-cell ...

Medical Devices

Stryker Q Guidance for Computer-assisted Surgery Cleared

FDA clears a Stryker 510(k) for its Q Guidance System for advanced planning and intraoperative guidance during open or percutaneous computer-assisted ...

Federal Register

Coronary Artery Disease Risk Indicators in Class 2

Federal Register notice: FDA classifies coronary artery disease risk indicators using acoustic heart signals into Class 2 (special controls).

Human Drugs

Coordinate on Drug Patent Oversight: Senators

Sens. Cassidy and Hassan call on FDA and the Patent and Trademark Office to better coordinate and communicate on drug patent applications that could d...

Human Drugs

Bill to Streamline Generic Drug Approvals

Sens. Hassan and Paul introduce a bill to require FDA to more clearly identify differences between a generic and its reference-listed drug.

Human Drugs

Novartis Gets Expanded OK for Kymriah

FDA grants Novartis accelerated approval for Kymriah (tisagenlecleucel) for treating adult patients with relapsed or refractory follicular lymphoma af...

Medical Devices

FDA Denies Most Parts of 4 Dental Amalgam Petitions

FDA denies most elements in four Consumers for Dental Choice petitions seeking additional agency actions to stop or reduce amalgam use in dentistry.

Human Drugs

Esophageal Cancer Indication for BMS Opdivo

FDA approves two indications involving Bristol-Myers Squibbs Opdivo in combination with other drugs for some esophageal cancers.

Human Drugs

Clinical Hold on Sanofi OTC Cialis Trial

FDA places a clinical hold on a Sanofi actual use trial to support its planned Rx-to-OTC switch for Cialis (tadalafil), which it licensed from Eli Lil...

Human Drugs

BioMarin Resubmitting Hemophilia A BLA in September

BioMarin Pharmaceutical plans to resubmit a BLA for valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, by the end of September that w...